New drug combo tested in fight against advanced stomach cancer
Disease control
Terminated
This study tested whether adding an experimental drug called DKN-01 to a standard immunotherapy (tislelizumab) and chemotherapy could better control advanced stomach or gastroesophageal cancer. It involved about 247 adults whose cancer could not be removed by surgery. The main go…
Phase: PHASE2 • Sponsor: Leap Therapeutics, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC